Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ahvaz Jundishapur University of Medical Sciences

In Vitro Activities of Six Antifungal Drugs Against Candida glabrata Isolates: An Emerging Pathogen

Amirrajab, Nasrin and Badali, Hamid and Didehdar, Mojtaba and Afsarian, Mohammad Hosein and Mohammadi, Rasoul and Lotfi, Nazanin and Shokohi, Tahereh (2016) In Vitro Activities of Six Antifungal Drugs Against Candida glabrata Isolates: An Emerging Pathogen. Jundishapur Journal of Microbiology, In pre (In pre). ISSN 2008-3645

[img]
Preview
Text
jjm-09-05-36638.pdf

Download (148kB) | Preview
Official URL: http://doi.org/10.5812/jjm.36638

Abstract

Background: Candida glabrata is a pathogenic yeast with several unique biological features and associated with an increased incidence rate of candidiasis. It exhibits a great degree of variation in its pathogenicity and antifungal susceptibility. Objectives: The aim of the present study was to evaluate the in vitro antifungal susceptibilities of the following six antifungal drugs against clinical C. glabrata strains: amphotericin B (AmB), ketoconazole (KTZ), fluconazole (FCZ), itraconazole (ITZ), voriconazole (VCZ), and caspofungin (CASP). Materials and Methods: Forty clinical C. glabrata strains were investigated using DNA sequencing. The in vitro antifungal susceptibility was determined as described in clinical laboratory standard institute (CLSI) documents (M27-A3 and M27-S4). Results: The sequence analysis of the isolate confirmed as C. glabrata and deposited on NCBI GenBank under the accession number no. KT763084-KT763123. The geometric mean MICs against all the tested strains were as follows, in increasing order: CASP (0.17 g/mL), VCZ (0.67 g/mL), AmB (1.1 g/mL), ITZ (1.82 g/mL), KTZ (1.85 g/mL), and FCZ (6.7 g/mL). The resistance rates of the isolates to CASP, FCZ, ITZ, VZ, KTZ, and AmB were 5%, 10%, 72.5%, 37.5%, 47.5%, and 27.5%, respectively. Conclusions: These findings confirm that CASP, compared to the other antifungals, is the potent agent for treating candidiasis caused by C. glabrata. However, the clinical efficacy of these novel antifungals remains to be determined.

Item Type: Article
Keywords: In Vitro Antifungal Susceptibility; Broth Microdilution; Candida glabrata
Subjects: R Medicine > R Medicine (General)
Depositing User: آقای بهرام سوسنی غریب وند
Date Deposited: 07 Nov 2016 10:27
Last Modified: 07 Nov 2016 10:27
URI: http://eprints.ajums.ac.ir/id/eprint/2559

Actions (login required)

View Item View Item